Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human malignancies and tends to be relatively resistant to conventional therapies. Activated Ras oncogene mutations are found in up to 90% of PDAC, leading to activation of the Ras/Raf/MEK/ERK signaling pathway. Sorafe...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Awasthi, Niranjan, Zhang, Changhua, Hinz, Stefan, Schwarz, Margaret A, Schwarz, Roderich E
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2013
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3618297/
https://ncbi.nlm.nih.gov/pubmed/23497499
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-9966-32-12
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki